Confusion is priced in.
Investors discount risk they cannot quantify.
We help biotech founders translate science into investor conviction — and funding.
Decks written for scientists may overwhelm investor audiences. Scientific milestones do not automatically translate into investor returns, and opportunistic story evolution can erode conviction and credibility.
Investors discount risk they cannot quantify.
More rounds of pitching, fewer term sheets. Your runway burns.
Investors walk when the narrative does not make the opportunity clear enough.
BioNarrative works at the point where deep biotech understanding meets investor logic and communication craft.
Not just slides. Every word earns its place in your story.
Market sizing, competitive positioning and exit scenarios — in the language investors use.
We understand the science and industry to position your innovation.
We build a clearer and compelling equity story increasing the probability of convincing investors.
A clear, compelling equity story built around your science.
Slides that balance data with conviction-building narrative.
Consistent language for every investor touchpoint.
Coaching so you can deliver your story with confidence.
A five-week working approach that moves from scientific and market evidence to a polished, investor-ready narrative.
Deep dive into your science, pipeline and competitive landscape. We extract the investable signal.
Craft your equity story, positioning and core messaging. Align on voice and tone.
Build pitch deck and materials with multiple rounds of feedback and refinement.
Final polish, Q&A prep and materials delivered. You walk in ready to close.
Core fundraising materials designed to work together as one consistent investor narrative.
We identify where investors may misread the company — then reframe the story around de-risking, value creation and competitive advantage.
Experience across global biopharma, life-science advisory, company building, commercial strategy and fundraising.
Gert helps founders and management teams translate complex science into clear, investable narratives, with focus on asset positioning, market opportunity and investor messaging.
Rasmus helps turn promising science into companies that can be financed, operationalised and built to last, spanning financial modelling, market entry, licensing, partnering and fundraising.
A compelling investor-ready narrative from slide one — designed for clearer positioning, stronger conviction and more effective fundraising conversations.